Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

372 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intensity-modulated radiotherapy allows escalation of the radiation dose to the pelvic lymph nodes in patients with locally advanced prostate cancer: preliminary results of a phase I dose escalation study.
Guerrero Urbano T, Khoo V, Staffurth J, Norman A, Buffa F, Jackson A, Adams E, Hansen V, Clark C, Miles E, McNair H, Nutting C, Parker C, Eeles R, Huddart R, Horwich A, Dearnaley DP. Guerrero Urbano T, et al. Among authors: hansen v. Clin Oncol (R Coll Radiol). 2010 Apr;22(3):236-44. doi: 10.1016/j.clon.2010.01.005. Epub 2010 Feb 19. Clin Oncol (R Coll Radiol). 2010. PMID: 20171852 Clinical Trial.
The Intensity-Modulated Pelvic Node and Bladder Radiotherapy (IMPART) Trial: A Phase II Single-Centre Prospective Study.
Tan MP, Harris V, Warren-Oseni K, McDonald F, McNair H, Taylor H, Hansen V, Sharabiani M, Thomas K, Jones K, Dearnaley D, Hafeez S, Huddart RA. Tan MP, et al. Among authors: hansen v. Clin Oncol (R Coll Radiol). 2020 Feb;32(2):93-100. doi: 10.1016/j.clon.2019.07.017. Epub 2019 Aug 8. Clin Oncol (R Coll Radiol). 2020. PMID: 31400946 Free PMC article. Clinical Trial.
Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI.
Kraft CS, Sims M, Silverman M, Louie TJ, Feuerstadt P, Huang ES, Khanna S, Berenson CS, Wang EEL, Cohen SH, Korman L, Lee C, Kelly CR, Odio A, Cook PP, Lashner B, Ramesh M, Kumar P, De A, Memisoglu A, Lombardi DA, Hasson BR, McGovern BH, von Moltke L, Pardi DS; ECOSPOR III and ECOSPOR IV investigators. Kraft CS, et al. Infect Dis Ther. 2024 Oct;13(10):2209-2210. doi: 10.1007/s40121-024-01036-8. Infect Dis Ther. 2024. PMID: 39212853 Free PMC article. No abstract available.
Decompression alone or with fusion for degenerative lumbar spondylolisthesis (Nordsten-DS): five year follow-up of a randomised, multicentre, non-inferiority trial.
Kgomotso EL, Hellum C, Fagerland MW, Solberg T, Brox JI, Storheim K, Hermansen E, Franssen E, Weber C, Brisby H, Algaard KRH, Furunes H, Banitalebi H, Ljøstad I, Indrekvam K, Austevoll IM; Nordsten collaborators. Kgomotso EL, et al. BMJ. 2024 Aug 7;386:e079771. doi: 10.1136/bmj-2024-079771. BMJ. 2024. PMID: 39111800 Free PMC article. Clinical Trial.
Bladder Tumor-Focused Adaptive Radiation Therapy: Clinical Outcomes of a Phase I Dose Escalation Study.
Hafeez S, Warren-Oseni K, Jones K, Mohammed K, El-Ghzal A, Dearnaley D, Harris V, Khan A, Kumar P, Lalondrelle S, McDonald F, Tan M, Thomas K, Thompson A, McNair HA, Hansen VN, Huddart RA. Hafeez S, et al. Among authors: hansen vn. Int J Radiat Oncol Biol Phys. 2025 Jan 1;121(1):165-175. doi: 10.1016/j.ijrobp.2024.07.2317. Epub 2024 Jul 26. Int J Radiat Oncol Biol Phys. 2025. PMID: 39069239 Free article. Clinical Trial.
Impact of on-trial IGRT quality assurance in an international adaptive radiotherapy trial for participants with bladder cancer.
Webster A, Francis M, Gribble H, Griffin C, Hafeez S, Hansen VN, Lewis R, McNair H, Miles E, Hall E, Huddart R; RAIDER Trial Management Group. Webster A, et al. Among authors: hansen vn. Radiother Oncol. 2024 Oct;199:110460. doi: 10.1016/j.radonc.2024.110460. Epub 2024 Jul 26. Radiother Oncol. 2024. PMID: 39069085 Free PMC article.
Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI.
Kraft CS, Sims M, Silverman M, Louie TJ, Feuerstadt P, Huang ES, Khanna S, Berenson CS, Wang EEL, Cohen SH, Korman L, Lee C, Kelly CR, Odio A, Cook PP, Lashner B, Ramesh M, Kumar P, De A, Memisoglu A, Lombardi DA, Hasson BR, McGovern BH, von Moltke L, Pardi DS; ECOSPOR III and ECOSPOR IV investigators. Kraft CS, et al. Infect Dis Ther. 2024 Oct;13(10):2105-2121. doi: 10.1007/s40121-024-01007-z. Epub 2024 Jun 28. Infect Dis Ther. 2024. PMID: 38941068 Free PMC article.
372 results